多西紫杉醇-海豹油纳米结构脂质载体的抗肿瘤活性评价

doi:10.3969/j.issn.1006-7795.2015.04.006

首都医科大学学报 ›› 2015, Vol. 36 ›› Issue (2): 185-191.doi: 10.3969/j.issn.1006-7795.2015.04.006

多西紫杉醇-海豹油纳米结构脂质载体的抗肿瘤活性评价

史凡¹, 崔纯莹¹, 吴建辉², 王玉记²

1. 首都医科大学化学生物学与药学院药剂学系, 北京 100069;
2. 首都医科大学化学生物学与药学院药药物化学系, 北京 100069

收稿日期:2014-12-08 出版日期:2015-04-21 发布日期:2015-04-16
通讯作者: 王玉记 E-mail:wangyuji@ccmu.edu.cn
基金资助:
"十二五"重大新药创制科技重大专项(2011ZX09302-007-01)。

Evaluation of anti-tumor activity of docetaxel loaded nanostructured lipid carriers with seal oil

Shi Fan¹, Cui Chunying¹, Wu Jianhui², Wang Yuji²

1. Department of Pharmaceutics, School of Chemical Biology and Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China;
2. Department of Medicinal Chemistry, School of Chemical Biology and Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China

Received:2014-12-08 Online:2015-04-21 Published:2015-04-16
Supported by:
This study was supported by Significant New Drugs Creation "Five-year" Plan Special Science and Technology Major(2011ZX09302-007-01).

摘要/Abstract

摘要： 目的探讨多西紫杉醇(docetaxel,DTX)海豹油脂质体的抗肿瘤活性以及与脂肪乳的比较。方法采用正交试验设计法筛选处方,通过高压乳匀法制备多西紫杉醇海豹油脂质体。测定其粒径、电位、包封率、体外释药、血浆中稳定性等。并采用四甲基偶氮唑盐[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,MTT]进行体外抗肿瘤活性研究,以及采用荷肉瘤S180 小鼠进行体内抗肿瘤活性研究,考察各组抑瘤率和存活率。结果多西紫杉醇海豹油脂质体的粒径在200 nm左右,Zeta电位为-30~-50 mV,包封率达95%以上。体外释放研究证明多西紫杉醇脂肪乳与多西紫杉醇海豹油脂质体具有一定的pH敏感性,且推测多西紫杉醇海豹油脂质体具有更强的缓释作用。血浆中稳定性研究证明多西紫杉醇脂肪乳与多西紫杉醇海豹油脂质体在血浆中较稳定,释放行为缓慢。结论由MTT法结果得多西紫杉醇海豹油脂质体、多西紫杉醇脂肪乳与DTX均表现出较强的细胞毒性作用,且多西紫杉醇海豹油脂质体具有一定的缓释作用。以荷肉瘤S180小鼠为模型的体内抗肿瘤活性研究表明多西紫杉醇脂肪乳与多西紫杉醇海豹油脂质体在血浆中12 h内累积释放量分别为(13.82±0.59)%与(12.91±0.60)%。说明剂型在血浆中较稳定,释放行为缓慢。另外, DTX组小鼠9 d存活率为0,多西紫杉醇脂肪乳组于9 d存活率为93.3%,而多西紫杉醇海豹油脂质体组小鼠9 d存活率为100%,说明多西紫杉醇海豹油脂质体使得耐受剂量提高,降低了药物的不良反应,提高用药安全性与用药的顺应性。

关键词: 多西紫杉醇, 纳米结构脂质载体, 脂肪乳, 海豹油, 抗肿瘤

Abstract: Objective To design and prepare the nanostructured lipid carriers(NLC) and the lipid emulsion(LE) containing seal oil, and the anti-cancer drug docetaxel(DTX) as a model drug. Methods The DTX-NLC was obtained by high pressure homogenization. The release of DTX-NLC and DTX-LE in vitro were determined by dynamic dialysis method in PBS with 0.5% DMSO(pH7.4 and pH5.4), and in plasma. In vitro anti-tumor studies of DTX-NLC and DTX-LE were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay. While, in vivo anti-tumor activities of DTX-NLC and DTX-LE were determined in S180 bearing mice. Results The morphology of DTX-NLC was in spherical shape with approximately 200 nm in diameter and the zeta potential ranged from -30 to -50 mV, and the encapsulation efficiency is about 95%.The release percentage of DTX-NLC is(4.30±0.32)% and (8.12±0.32)% in PBS with 0.5% DMSO at pH 7.4 and pH 5.4, and the releasing of the DTX from the DTX-NLC was more sustained from the DTX-LE. The DTX-NLC and DTX-LE showed a good stability in plasma. MTT assays showed that the DTX-NLC, DTX-LE and DTX could inhibit the growth of the cells. Conclusion Vivo anti-tumor studies in S180 bearing mice showed thatthe NLC had better sustained-release effect than that of LE, and extend the dosing interval further, increase tolerated dose, reduce the side effects of drugs, and improve the compliance of medication safety and medication.

Key words: docetaxel, nanostructured lipid carrier, lipid emulsion, seal oil, anti-tumor

中图分类号:

R965.1

史凡, 崔纯莹, 吴建辉, 王玉记. 多西紫杉醇-海豹油纳米结构脂质载体的抗肿瘤活性评价[J]. 首都医科大学学报, 2015, 36(2): 185-191.

Shi Fan, Cui Chunying, Wu Jianhui, Wang Yuji. Evaluation of anti-tumor activity of docetaxel loaded nanostructured lipid carriers with seal oil[J]. Journal of Capital Medical University, 2015, 36(2): 185-191.

参考文献

[1] Attama A A, Schicke B C, Paepenmüller T, et al. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid:characterization[J]. Eur J Pharm Biopharm, 2007,67(1):48-57.
[2] Müller R H, Radtke M, Wissing S A. Nanostructured lipid matrices for improved microencapsulation of drugs[J]. Int J Pharm, 2002,242(1):121-128.
[3] Kovacevic A, Savic S, Vuleta G, et al. Polyhydroxy surfactants for the formulation of lipid nanoparticles(SLN and NLC):effects on size, physical stability and particle matrix structure[J]. Int J Pharm, 2011,406(1):163-172.
[4] Wissing S, Lippacher A, Müller R. Investigations on the occlusive properties of solid lipid nanoparticles(SLN)[J]. J Cosmetic Sci, 2000,52(5):313-324.
[5] Seki J, Sonoke S, Saheki A, et al. A nanometer lipid emulsion, lipid nano-sphere(LNS), as a parenteral drug carrier for passive drug targeting[J]. Int J Pharm, 2004,273(1-2):75-83.
[6] Tamilvanan S. Oil-in-water lipid emulsions:implications for parenteral and ocular delivering systems[J]. Prog Lipid Res, 2004,43(6):489-533.
[7] Tamjidi F, Shahedi M, Varshosaz J, et al. Nanostructured lipid carriers(NLC):a potential delivery system for bioactive food molecules[J]. Innov Food Sci Emerg Technol, 2013,19:29-43.
[8] Nicoletti M I, Colombo T, Rossi C, et al. IDN5109, a taxane with oral bioavailability and potent antitumor activity[J]. Cancer Res, 2000,60(4):842-846.
[9] Thiesen J, Krämer I. Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefine containers[J]. Pharm World Sci, 1999,21(3):137-141.
[10] Hu F Q, Jiang S P, Du Y Z, et al. Preparation and characteristics of monostearin nanostructured lipid carriers[J]. Inte J Pharm, 2006,314(1):83-89.
[11] Yuan H, Wang L, Du Y, et al. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification[J]. Colloids Surf B Biointerfaces, 2007,60(2):174-179.
[12] Müller R H, Radtke M, Wissing S A. Solid lipid nanoparticles(SLN) and nanostructured lipid carriers(NLC) in cosmetic and dermatological preparations[J]. Adv Drug Deliv Rev, 2002,54(S):131-155.

多西紫杉醇-海豹油纳米结构脂质载体的抗肿瘤活性评价

Evaluation of anti-tumor activity of docetaxel loaded nanostructured lipid carriers with seal oil

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

本文评价

[1]	李飞阳, 崔纯莹, 王玉记, 吴建辉. 阿霉素脂质体的制备及抗肿瘤活性研究[J]. 首都医科大学学报, 2015, 36(2): 157-160.
[2]	邢璐, 崔纯莹, 王玉记, 房晨婕, 吴建辉. 巯嘌呤/维拉帕米-介孔氧化硅释药系统的构建及逆转耐药活性研究[J]. 首都医科大学学报, 2015, 36(2): 161-165.
[3]	魏丽艳, 崔纯莹, 吴建辉, 王玉记. 以海豹油为基质的多西紫杉醇脂肪乳的制备及其抗肿瘤活性研究[J]. 首都医科大学学报, 2015, 36(2): 192-198.
[4]	李雪梅, 王玉记, 吴建辉, 崔纯莹. RGD脂肪醇与17-AAG脂质体的制备及抗肿瘤活性研究[J]. 首都医科大学学报, 2015, 36(2): 172-177.
[5]	闫岩, 王玉记, 吴建辉, 崔纯莹. 17-AAG聚氰基丙烯酸正丁酯纳米粒的制备及抗肿瘤活性研究[J]. 首都医科大学学报, 2015, 36(2): 178-184.
[6]	崔永, 柳明亮, 吴炳群, 段新春, 龚民. 紫杉醇-顺铂联合药物控释系统对肺腺癌细胞系A549细胞生长的抑制作用[J]. 首都医科大学学报, 2014, 35(6): 694-697.
[7]	张晶, 刘伟, 陈云雨, 司书毅. 以保罗样激酶1为靶点的抗肿瘤药物的筛选及活性评价[J]. 首都医科大学学报, 2014, 35(3): 337-343.
[8]	徐艳霞;赵明;王玉记;吴建辉;李莉;张建伟;康贵峰;彭师奇. 药物设计中的伪肽先导结构的发现[J]. 首都医科大学学报, 2010, 31(5): 614-622.
[9]	李金凤;张震宇;王淑珍;刘晋玮. 卵巢癌细胞和脐血树突状细胞融合瘤苗的体外培养与免疫原性的研究[J]. 首都医科大学学报, 2007, 28(5): 604-608.